Table 1

GLP-1 receptor agonists with completed cardiovascular outcomes trials to date

GLP-1 RAAdministrationHalf-lifeStarting doseMaximum doseRenal function*
Lixisenatide (Adlyxin)Daily3 hours10 mcg20 mcgNot recommended eGFR <15
Liraglutide (Victoza)Daily13 hours0.6 mg1.8 mgNo dosage adjustment
Semaglutide (Ozempic)Weekly1 week0.25 mg1.0 mgNo dosage adjustment
Exenatide QW (Bydureon)Weekly2 weeks2.0 mg2.0 mgNot recommended eGFR <45
Albiglutide† (Eperzan)Weekly5 days30 mg50 mgNot recommended eGFR <15
Dulaglutide (Trulicity)Weekly5 days0.75 mg1.5 mgNo dosage adjustment
Oral semaglutide (Rybelsus)Daily1 week3 mg14 mgNo dosage adjustment
  • *Drug manufacturer dosage adjustments for renal impairment.

  • †Not currently being marketed.

  • eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; QW, every week; GLP-1 RA, glucagon-like peptide 1 receptor agonist.